8-K: Altria Narrows 2025 EPS Guidance Amidst Mixed Q2 Results and E-Vapor Impairment

Altria Group, Inc. reported mixed second-quarter and first-half 2025 business results, narrowing its full-year adjusted diluted EPS guidance to a range of $5.35 to $5.45, representing 3.0% to 5.0% growth from 2024.

Summary

• Net revenues for Q2 2025 decreased 1.7% to $6,102 million, while revenues net of excise taxes increased 0.2% to $5,290 million.
• Reported diluted EPS for Q2 2025 decreased 36.2% to $1.41, primarily due to the 2024 gain on the sale of IQOS commercialization rights.
• Adjusted diluted EPS for Q2 2025 increased 8.3% to $1.44, driven by higher adjusted operating companies income (OCI) and fewer shares outstanding.
• For the first half of 2025, net revenues decreased 3.6% to $11,361 million, and revenues net of excise taxes decreased 1.9% to $9,809 million.
• First-half 2025 reported diluted EPS decreased 40.2% to $2.04, largely due to the 2024 IQOS sale gain.
• First-half 2025 adjusted diluted EPS increased 7.2% to $2.67, primarily due to higher adjusted OCI, fewer shares outstanding, and a lower adjusted tax rate.
• The company repurchased 4.7 million shares for $274 million in Q2 2025 at an average price of $58.63, and 10.4 million shares for $600 million in the first half at an average price of $57.71.
• As of June 30, 2025, $400 million remained under the currently authorized $1 billion share repurchase program, expected to be completed by December 31, 2025.
• Dividends of $1.7 billion were paid in Q2 2025 and $3.5 billion in the first half of 2025.
• Smokeable products segment domestic cigarette shipment volume decreased 10.2% in Q2 2025 and 11.9% in the first half of 2025.
• Marlboro retail share of the total cigarette category was 41.0% in Q2 2025, a decrease of 0.9 share points versus the prior year.
• Oral tobacco products segment reported domestic shipment volume decreased 1.0% in Q2 2025 and 2.9% in the first half of 2025.
• on! nicotine pouches total U.S. oral tobacco category share was 8.7% in Q2 2025, an increase of 0.7 share points versus the prior year.
• The U.S. nicotine pouch category grew to 52.0% of the U.S. oral tobacco category in Q2 2025, an increase of 10.0 share points versus the prior year.
• A non-cash impairment charge of $873 million was recorded to the e-vapor reporting unit goodwill in the first half of 2025.
• Net pre-tax expense items of $95 million were recorded in the first half of 2025 related to acquisition and disposition, including $70 million for the ITC exclusion order on NJOY ACE.

Sentiment

Score: 6

Explanation: The results present a mixed picture. While adjusted EPS growth and strong oral tobacco performance are positive indicators of the company's strategic transition, the significant decline in reported EPS (due to prior year's IQOS sale gain), continued decline in cigarette volumes, and the e-vapor goodwill impairment are notable negatives. The narrowed EPS guidance with a raised lower end suggests stability and confidence in the core business and smoke-free transition, but challenges in the combustible and e-vapor segments remain.

Positives

• Adjusted diluted EPS increased 8.3% in Q2 2025 to $1.44 and 7.2% in H1 2025 to $2.67, indicating strong underlying operational performance.
• The oral tobacco products segment's net revenues increased 5.9% in Q2 and 3.3% in H1, primarily driven by higher pricing.
• on! nicotine pouches delivered strong performance and was the substantial driver of the oral tobacco segment's growth in the quarter.
• Adjusted OCI for oral tobacco products increased 10.9% in Q2 and 5.5% in H1, with margins increasing by 3.1 percentage points to 68.7% in Q2 and 1.4 percentage points to 68.9% in H1.
• Returned significant value to shareholders, with over $4 billion delivered through dividends ($3.5 billion) and share repurchases ($600 million) in the first half of the year.
• The $1 billion share repurchase program is on track to be completed by December 31, 2025, with $400 million remaining as of June 30, 2025.
• Adjusted OCI margins for smokeable products increased by 2.9 percentage points to 64.5% in Q2 and 3.5 percentage points to 64.5% in H1, despite volume declines.
• Reported cigar shipment volume increased 3.7% in Q2 and 0.6% in H1.

Negatives

• Net revenues decreased 1.7% in Q2 2025 and 3.6% in H1 2025, primarily driven by lower net revenues in the smokeable products segment.
• Reported diluted EPS decreased significantly by 36.2% in Q2 2025 and 40.2% in H1 2025, primarily due to the substantial gain on the sale of IQOS commercialization rights in 2024.
• Smokeable products segment net revenues decreased 2.5% in Q2 and 4.1% in H1, primarily due to lower shipment volume.
• Domestic cigarette shipment volume decreased 10.2% in Q2 and 11.9% in H1, impacted by industry decline, growth of flavored disposable e-vapor products (many illicit), and discretionary income pressures.
• Marlboro retail share of the total cigarette category decreased 0.9 share points in Q2 and 1.0 share point in H1.
• The cigarette industry discount retail share increased 1.9 share points in Q2 and 1.8 share points in H1, indicating a shift in consumer purchasing behavior towards lower-priced options.
• Oral tobacco products segment reported domestic shipment volume decreased 1.0% in Q2 and 2.9% in H1, driven by retail share losses for MST products.
• Skoal and Copenhagen shipment volumes experienced notable declines, with Skoal down 8.8% in Q2 and 11.6% in H1, and Copenhagen down 7.7% in Q2 and 8.6% in H1.
• on!'s share of the nicotine pouch category decreased 2.3 share points in Q2 and 0.9 share points in H1, despite overall category growth.
• A non-cash impairment charge of $873 million was recorded to the e-vapor reporting unit goodwill in the first half of 2025, suggesting underperformance or challenges in this segment.
• Net pre-tax expense items of $95 million were incurred in H1 2025 related to acquisition and disposition, including $70 million due to the ITC exclusion order on NJOY ACE.
• Lower income from the equity investment in ABI and higher financing costs partially offset adjusted diluted EPS growth in H1 2025.

Risks

• Inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior.
• Inability to compete effectively in the evolving tobacco market.
• The growth of the e-vapor category, particularly illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume.
• The impact of illicit trade in tobacco products and the sale of products designed to avoid the regulatory framework.
• Failure to develop and commercialize innovative products, including tobacco products that may reduce health risks.
• Changes in macroeconomic and geopolitical conditions, including inflation and tariffs, that result in shifts in adult tobacco consumer disposable income and purchasing behavior, such as choosing lower-priced brands.
• Unfavorable outcomes with respect to litigation proceedings or governmental investigations, including significant monetary and non-monetary remedies and importation bans.
• Risks associated with significant federal, state, and local government actions, including FDA regulatory actions and inaction.
• The risk that regulators, including the FDA, and courts may interpret laws, rules, and regulations applicable to products differently than the company does.
• Increases in tobacco product-related taxes.
• Failure to complete or manage successfully strategic transactions, including acquisitions, dispositions, joint ventures, and investments in third parties, or realize the anticipated benefits.
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts.
• Reliance on a few significant facilities and a small number of key suppliers, distributors, and distribution chain service providers.
• The risk that the company may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment.
• Risks associated with the Optimize & Accelerate initiative, including business continuity, internal control over financial reporting, and the ability to recognize expected savings.
• The risk that the company could decide, or be required, to recall products.
• The various risks related to health epidemics and pandemics.
• Inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage.
• Risks associated with various U.S. and foreign laws and regulations due to international business operations.
• Risks concerning a challenge to tax positions, an increase in the income tax rate, or other changes to federal or state tax laws.
• Risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters.
• Disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets.
• A downgrade or potential downgrade of credit ratings.
• The impact of heightened focus by investors and other stakeholders on corporate responsibility matters.
• The failure of information systems to function as intended, or cyber-attacks or security breaches.
• Failure to comply with laws related to personal data protection, privacy, and artificial intelligence.
• The risk that the expected benefits of the investment in ABI may not materialize.
• The risks associated with the investment in Cronos, including legal, regulatory, and reputational risks.

Future Outlook

Altria narrowed its 2025 full-year adjusted diluted EPS guidance to a range of $5.35 to $5.45, representing a growth rate of 3.0% to 5.0% from a 2024 base of $5.19. This guidance anticipates moderating EPS growth due to the lower share count from the 2024 accelerated share repurchase program completion and the Master Settlement Agreement legal fund expiration benefit in the fourth quarter. It also considers the current estimated impact of increased tariffs on costs, assumes limited impact on combustible and e-vapor product volumes from illicit product enforcement, and expects ACE not to return to the marketplace this year. The guidance range includes planned investments in support of the company's Vision, such as marketplace activities for smoke-free products and continued smoke-free product research, development, and regulatory preparation expenses, along with lower expected net periodic benefit income. The company will continue to monitor conditions related to the economy, adult tobacco consumer dynamics, illicit product enforcement, and regulatory, litigation, and legislative developments.

Management Comments

• "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses."
• "In oral tobacco, on! delivered strong performance and was the substantial driver of the segments growth in the quarter."
• "And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases."
• "We are raising the lower-end of our 2025 full-year guidance and now expect to deliver adjusted diluted EPS in a range of $5.35 to $5.45."

Industry Context

The filing highlights the ongoing transformation within the tobacco industry, characterized by a significant decline in traditional combustible cigarette volumes, which Altria's domestic cigarette shipment volume reflects (down 10.2% in Q2). This decline is exacerbated by the proliferation of flavored disposable e-vapor products, many of which are believed to be illicit, and by economic pressures influencing consumer purchasing patterns towards discount brands. Conversely, the oral tobacco category, particularly oral nicotine pouches, is experiencing robust growth, with the U.S. nicotine pouch category expanding to 52.0% of the total U.S. oral tobacco category in Q2. Altria's 'on!' brand is a key contributor to this growth, aligning with the company's strategic 'Moving Beyond Smoking' vision. However, the impairment charge on the e-vapor reporting unit goodwill and the ITC exclusion order on NJOY ACE underscore the intense competition, regulatory challenges, and market volatility within the smoke-free segment, particularly from unregulated products.

Comparison to Industry Standards

• Altria's domestic cigarette shipment volume decreased by an estimated 10.5% (adjusted for trade inventory movements) in Q2 2025, which is a faster decline than the total estimated domestic cigarette industry volume decrease of 8.5%, indicating Altria's cigarette segment is losing market share.
• Marlboro's retail share of the total cigarette category was 41.0% in Q2 2025, a decrease of 0.9 share points versus the prior year, while the cigarette industry discount retail share increased by 1.9 share points to 31.2%, suggesting a consumer shift towards lower-priced alternatives.
• The U.S. nicotine pouch category grew to 52.0% of the U.S. oral tobacco category in Q2 2025, an increase of 10.0 share points versus the prior year, demonstrating strong industry-wide growth in this segment.
• Altria's on! nicotine pouches total U.S. oral tobacco category share was 8.7% in Q2 2025, an increase of 0.7 share points versus the prior year, but its share of the nicotine pouch category specifically was 16.7%, a decrease of 2.3 share points versus the prior year, indicating that while on! is growing, it is losing share within the rapidly expanding nicotine pouch sub-category to competitors.
• The non-cash impairment of $873 million to the e-vapor reporting unit goodwill in H1 2025 suggests that Altria's e-vapor business (NJOY) is underperforming initial expectations or facing significant market challenges, potentially due to competition from illicit products or slower-than-expected adoption, contrasting with the overall growth in the smoke-free category.

Legal Proceedings

• Net pre-tax expense items of $95 million in H1 2025 related to acquisition and disposition, including $70 million related to the International Trade Commission's (ITC) exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States.
• Pre-tax charges of $45 million in H1 2025 for tobacco and health and certain other litigation items.
• The company lists 'unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans' as a key risk factor.

Stakeholder Impact

• Shareholders: The company returned over $4 billion to shareholders in H1 2025 through dividends and share repurchases, indicating a strong commitment to shareholder returns. Adjusted EPS growth is positive, but the significant decline in reported EPS due to the prior year's IQOS sale gain and the e-vapor impairment could be areas of concern.
• Consumers: Discretionary income pressures are influencing adult tobacco consumer purchasing patterns, leading to a shift towards lower-priced and discount cigarette brands. The continued growth of flavored disposable e-vapor products, many of which are believed to be illicit, impacts consumer choices and the competitive landscape.
• Employees: The 'Optimize & Accelerate initiative' is mentioned, which is designed to achieve cost savings, potentially implying restructuring or efficiency measures that could impact employees, though no direct details are provided.
• Regulatory Authorities: The filing highlights ongoing challenges with illicit e-vapor products and the ITC exclusion order on NJOY ACE, underscoring continued regulatory scrutiny and enforcement efforts in the tobacco and e-vapor markets.

Next Steps

• Completion of the $1 billion share repurchase program by December 31, 2025.
• Continued monitoring of economic conditions, adult tobacco consumer dynamics, illicit product enforcement, and regulatory/litigation developments.
• Planned investments in support of the Vision, including marketplace activities for smoke-free products and continued smoke-free product research, development, and regulatory preparation expenses.

Key Dates

Recommendation

Altria's Q2 and H1 2025 results present a mixed bag. While adjusted EPS growth and strong performance in the oral tobacco segment (driven by on!) are positive indicators of the company's 'smoke-free' transition strategy, the continued decline in the core combustible cigarette business and the significant impairment charge related to the e-vapor unit (NJOY) are concerning. The narrowed full-year EPS guidance, with a raised lower end, provides some stability, but the underlying challenges of declining traditional product volumes and intense competition in the e-vapor space (including illicit products) persist. The company's commitment to shareholder returns through dividends and share repurchases is strong. Given the ongoing strategic transition, the stable but challenged core business, and the mixed performance in new categories, a 'Hold' recommendation is appropriate for investors seeking income and exposure to the evolving tobacco market, but who should remain cautious about the long-term decline of combustibles and the competitive landscape of smoke-free alternatives.

Keywords

Tobacco, Cigarettes, Oral Tobacco, Nicotine Pouches, Marlboro, on!, NJOY, Altria, MO, Earnings, Financial Results, EPS, Dividends, Share Repurchase, Smoke-free Products, FDA, Regulation, Consumer Staples, Risk Management